Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
JIB

Benztropine Reverses Multiple Sclerosis in Animal Models

By BiotechDaily International staff writers
Posted on 22 Oct 2013
Image: This study showed that the drug benztropine led to the repair of multiple sclerosis-damaged nerve fibers in animal models (Photo courtesy of Dr. Luke Lairson, The Scripps Research Institute).
Image: This study showed that the drug benztropine led to the repair of multiple sclerosis-damaged nerve fibers in animal models (Photo courtesy of Dr. Luke Lairson, The Scripps Research Institute).
Autoimmune disease researchers have reported the successful use of the Parkinson's disease drug benztropine [benzatropine (INN)] for treatment of animal models of multiple sclerosis.

Benztropine is a centrally acting anticholinergic/antihistamine agent resulting from the combination of the tropine portion of the atropine molecule and the benzohydryl portion of diphenhydramine. It is used in patients to reduce the side effects of antipsychotic treatment, such as pseudoparkinsonism and dystonia. Benztropine is also a second-line drug for the treatment of Parkinson's disease. It improves tremor, but not rigidity and bradykinesia.

Progressive phases of multiple sclerosis are associated with inhibited differentiation of the progenitor cell population that generates the mature oligodendrocytes required for remyelination and disease remission. To identify selective inducers of oligodendrocyte differentiation, investigators at The Scripps Research Institute (La Jolla, CA, USA) performed an image-based screen for myelin basic protein (MBP) expression using primary rat optic-nerve-derived progenitor cells. They screened over 100,000 chemical compounds for any that could potently induce oligodendrocyte progenitor cells to differentiate.

The investigators reported in the October 9, 2013, online edition of the journal Nature that benztropine was among the most effective of the compounds that were screened. Furthermore, it significantly decreased clinical severity in the experimental autoimmune encephalomyelitis (EAE) model of relapsing-remitting multiple sclerosis when administered alone or in combination with approved immunosuppressive treatments for multiple sclerosis.

Evidence from a cuprizone-induced model of demyelination, in vitro and in vivo T-cell assays, and EAE adoptive transfer experiments indicated that the observed efficacy of the drug resulted directly from an enhancement of remyelination rather than immune suppression. Pharmacological studies indicated that benztropine functioned by a mechanism that involved direct antagonism of M1 and/or M3 muscarinic receptors.

“We are excited about these results, and are now considering how to design an initial clinical trial,” said senior author Dr. Luke L. Lairson, assistant professor of chemistry at The Scripps Research Institute. “We are also looking at some of the other, relatively unknown molecules that we identified in our initial screen, to see if any of those has better clinical potential than benztropine.”

Related Links:

The Scripps Research Institute



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Alternative splicing produces two protein isoforms (Photo courtesy of Wikimedia Commons).

Key Regulator of Cancer-Inducing Alternative Splicing Identified

Cancer researchers have identified the splicing factor RBM4 (RNA-binding protein 4) as a key determinant in processes that prevent tumor development and spread. RBM4 is known to be crucial to gene splicing... Read more

Therapeutics

view channel
Image: Hair follicle (blue) being attacked by T cells (green) (Photo courtesy of Christiano Lab/Columbia University Medical Center).

Hair Restoration Method Clones Patients’ Cells to Grow New Hair Follicles

Researchers have developed of a new hair restoration approach that uses a patient’s cells to grow new hair follicles. In addition, the [US] Food and Drugs Administration (FDA) recently approved a new drug... Read more

Lab Technologies

view channel
Image: Leica Microsystems launches the inverted research microscope platform Leica DMi8 (Photo courtesy of Leica Microsystems).

New Inverted Microscope Designed to Readily Adapt to Changing Research Demands

A new inverted microscope for biotech and other life science laboratories was designed to readily accommodate modifications and upgrades to allow it to keep current with changing research demands and interests.... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.